At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 533 enrolled
Drug / intervention
Dasotralinedrug
Likely dose
Dasotraline 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder
In Brief
A Phase 3 clinical trial evaluating Dasotraline for Binge Eating Disorder. Completed, enrolled 533 participants across 57 sites.
Detailed Summary
Binge Eating Disorder Extension Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge Eating Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartFeb 2016
Primary CompletionJun 2019
TodayJul 2026
First PostedFeb 17, 2016
Enrollment StartFeb 29, 2016
Primary CompletionJun 24, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.4 years ago
Interventions
Dasotralinedrug
Dasotraline 4, 6, 8 mg flexibly dosed once daily